Version history

{
  "session_id": "sess_SDA-BIOMNI-PROTEOMI-c4a33049",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Differential Protein Expression in Alzheimer's Disease: Hypothesis Generation\n\n## Hypothesis 1: Synaptic Vesicle Trafficking Proteins Exhibit Coordinated Downregulation Across AD Brain and CSF\n\n**Title:** Loss of presynaptic terminal proteins (SNAP91, SYT1) as a replicated cross-cohort signature of synaptic degeneration in AD\n\n**Description:** SNAP91 (synaptosome-associated protein of 91 kDa) and SYT1 (synaptotagmin-1) are critical regulators of synaptic vesicle docking and neurotransmitter release. Proteomics from ROSMAP and Banner Sun cohorts demonstrate ~40-60% reduction in AD prefrontal cortex. We hypothesize that these proteins are shed into CSF proportionally to synaptic loss, creating a replicable biomarker signature. This reflects the well-established early synaptic dysfunction in AD (spine loss precedes tangle formation) and would validate across all three cohorts due to the universal nature of synaptic degeneration.\n\n**Target proteins:** SNAP91, SYT1\n\n**Confidence:** 0.78\n\n---\n\n## Hypothesis 2: Astrocyte Reactivity Markers GFAP/YKL-40 Show Consistent Elevation Replicated Across Cohorts\n\n**Title:** GFAP elevation in AD brain tissue and CSF reflects reactive astrogliosis replicating across independent cohorts\n\n**Description:** Glial fibrillary acidic protein (GFAP) is the canonical intermediate filament of astrocytes. In AD, GFAP is markedly upregulated (>3-fold in ROSMAP dorsolateral cortex) due to reactive astrogliosis in response to Aβ deposition and neuronal injury. We hypothesize that this elevation will replicate across Banner Sun Health and Emory cohorts, with a stronger effect in early-stage AD (\"mild cognitive impairment\" equivalent) than late-stage, consistent with reactive gliosis being an early compensatory response. CSF GFAP has emerged as a superior performer compared to CSF tau/Aβ42 in some head-to-head studies (Benedet et al., 2021).\n\n**Target proteins:** GFAP, CHIT1 (YKL-40)\n\n**Confidence:** 0.82\n\n---\n\n## Hypothesis 3: NPTX2 (Neuronal Pentraxin 2) Downregulation Reflects Excitatory Synapse Impairment Across AD Tissues\n\n**Title:** NPTX2 deficiency signals impaired excitatory synapse remodeling and predicts cognitive decline across cohorts\n\n**Description:** NPTX2 is a member of the neuronal pentraxin family critical for AMPA receptor clustering at excitatory synapses. Recent proteomic studies (Johnson et al., 2022, ROSMAP) reveal ~50% NPTX2 reduction in AD entorhinal cortex. Mechanistically, NPTX2 downregulation impairs synaptic plasticity and memory consolidation, creating a feedforward cycle of excitotoxicity. We hypothesize this will replicate in Banner Sun Health and Emory cohorts as both a brain tissue and CSF marker, with NPTX2 levels correlating inversely with NFT burden (Braak stage) and cognitive decline rate.\n\n**Target protein:** NPTX2\n\n**Confidence:** 0.71\n\n---\n\n## Hypothesis 4: Mitochondrial Electron Transport Chain Proteins Show Coordinated Reduction Replicating Across AD Cohorts\n\n**Title:** ETC complex I/IV subunit downregulation reflects bioenergetic failure and replicates across ROSMAP, Banner Sun, and Emory cohorts\n\n**Description:** Alzheimer's disease brains exhibit well-documented mitochondrial dysfunction, including reduced complex I (NDUFB8) and complex IV (COX1) activity. Using DIA proteomics, we hypothesize that subunits of the electron transport chain (MT-ND1, MT-ND2, COX1, ATP5F1A) will show coordinated ~30-40% reduction in AD prefrontal cortex, replicating across all three cohorts. This reflects the mitochondrial cascade hypothesis (Swerdlow et al., 2014) where bioenergetic failure is both a downstream consequence of Aβ toxicity and an upstream driver of neurodegeneration. Critically, mitochondrial proteins will show stronger correlation with *neuronal* markers (NeuN+ fraction) than whole-tissue homogenates.\n\n**Target proteins:** MT-ND1, MT-ND2, COX1, ATP5F1A\n\n**Confidence:** 0.69",
  "tokens_used": "976"
}